Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Amortizatization of Intangibles (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Amortizatization of Intangibles for 12 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Amortizatization of Intangibles rose 144.26% year-over-year to $1.4 million, compared with a TTM value of $6.7 million through Sep 2025, up 235.46%, and an annual FY2024 reading of $5.3 million, up 3537.67% over the prior year.
  • Amortizatization of Intangibles was $1.4 million for Q3 2025 at CytomX Therapeutics, up from $37000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $5.2 million in Q4 2024 and bottomed at -$5.0 million in Q4 2023.
  • Average Amortizatization of Intangibles over 5 years is $358842.1, with a median of $36000.0 recorded in 2022.
  • Peak annual rise in Amortizatization of Intangibles hit 80700.0% in 2023, while the deepest fall reached 14119.44% in 2023.
  • Year by year, Amortizatization of Intangibles stood at -$382000.0 in 2021, then surged by 109.42% to $36000.0 in 2022, then plummeted by 14119.44% to -$5.0 million in 2023, then skyrocketed by 203.07% to $5.2 million in 2024, then crashed by 72.82% to $1.4 million in 2025.
  • Business Quant data shows Amortizatization of Intangibles for CTMX at $1.4 million in Q3 2025, $37000.0 in Q2 2025, and $36000.0 in Q1 2025.